Skye Bioscience, Inc.
SKYE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $165,776 | $63,047 | $113,112 |
| - Cash | $18,441 | $23,838 | $46,421 | $68,416 |
| + Debt | $120 | $368 | $412 | $456 |
| Enterprise Value | – | $142,305 | $17,037 | $45,152 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$12,576 | -$17,434 | -$10,922 | -$9,618 |
| % Margin | – | – | – | – |
| Net Income | -$12,755 | -$17,625 | -$11,103 | -$9,746 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.32 | -0.44 | -0.28 | -0.24 |
| % Growth | 27.3% | -57.1% | -16.7% | – |
| Operating Cash Flow | -$13,364 | -$10,746 | -$9,185,480 | -$8,173 |
| Capital Expenditures | -$0 | -$0 | -$6,312 | -$50 |
| Free Cash Flow | -$13,364 | -$10,746 | -$9,191,792 | -$8,223 |